Rabbit antithymocyte globulin (Thymoglobulin s ) is commonly used as graft-versus-host disease (GvHD) prophylaxis. Since we found similar total CD8 T cell numbers in patients with and without Thymoglobulin s therapy within the first six months after allogeneic hematopoietic stem cell transplantation, we have analyzed the reconstitution of the CD8 T cell compartment in detail. After T cell-depletion, higher and more sustained proliferative capacity of memory CD8 T cells resulted in their rapid expansion, whereas the fraction of naive CD8 T cells decreased. Importantly, this shift towards effector memory CD8 T cells did not accelerate the incidence of GvHD.
Introduction
One of the major complications associated with allogeneic hematopoietic stem cell transplantation (alloHSCT) is the high incidence of acute graft-versus-host disease (GvHD) caused by donor T-lymphocytes. Depletion of donor T-lymphocytes is a wellestablished therapeutic option for GvHD-prophylaxis. Recently, we showed a sustained depletion of conventional and regulatory CD4 T cells in patients treated with ATG-Genzyme ™ (Thymoglobulin s , ATG-G) [1] , a polyclonal antibody preparation containing a broad spectrum of antibodies directed against T cells [2] and potentially thymic stromal cells. Interestingly, total CD8 T cell counts were similar in ATG-G treated and untreated patients [1] . In principle, T cell recovery after transplantation can take place through thymus dependent regeneration as well as by proliferation of existing T cells [3] . Here, we addressed whether the rapid CD8 T cell recovery after ATG-G depletion resulted from accelerated CD8 T cell regeneration or increased peripheral CD8 T cell proliferation and in how far this influenced GvHD incidence. Therefore, we studied the distribution of different CD8 T cell subsets and their proliferative capacity in ATG-G treated patients of the same patient cohort.
Material and methods
A detailed description of methods and patient cohorts can be found in Na et al. [1] (approval by the Charité -Berlin local ethics committee no. EA4/128/09). Briefly, we compared CD8 T cell reconstitution in 12 alloHSCT patients receiving ATG-G according to standard procedure protocols (ATG-G group, for d þ180: n ¼11) with 8 alloHSCT patients not receiving ATG-G (noATG-G group, for dþ 180: n¼ 3). Patient characteristics and clinical outcome are Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/lrr presented in Table 1 . Indications for transplantation were hematologic malignancies in all cases (AML n¼ 17, ALL n¼ 2, CLL n ¼1). Patients received ATG-G additionally to standard conditioning regimens if transplanted with grafts from matched-unrelated donors (MUD) as opposed to matched related donors (MRD) in the noATG-G group. One patient receiving an MUD graft did not receive ATG-G.
Multicolor flow cytometry (Becton Dickinson LSRII supported by FlowJo 9.3 software, TreeStar) was used to identify different CD8 T cell subsets after standard staining procedures of peripheral blood mononuclear cells (PBMC) from fresh heparinized blood samples. The following antibodies were used to characterize the CD8 T cell subsets: anti-CD3 APC/Cy7 (clone UCHT1; BioLegend), anti-CD4 Alexa Fluor 700 (clone RPA-T4; BioLegend), anti-CD8 V500 (clone RPA-T8; BD Biosciences), anti-CD45RA PerCP/Cy5.5 (clone HI100; BioLegend), anti-CD45RO Pacific Blue (clone UCHL1; BioLegend), and anti-CD197 (CCR7) Alexa Fluor 488 (clone TG8/ CCR7; BioLegend). For evaluation of Ki67 expression stainings were performed using anti-CD3 APC/Cy7 (clone UCHT1; BioLegend), anti-CD4 Alexa Fluor 700 (clone RPA-T4; BioLegend), anti-CD8 V500 (clone RPA-T8; BD Horizon), anti-CD45RA eFlour605 (clone HI100; eBioscience) and anti-Ki67 FITC (clone B56, BD Pharmingen). CD3 T cell counts were obtained by staining whole blood samples with CD3-Cy5 (clone UCTH-1, DRFZ, Berlin) and using BD TruCount TM controls (BD Biosciences). For group comparisons the Mann-Whitney-U test was used (GraphPad Software, La Jolla, CA).
Results
Analysis of the CD3 T cell compartment revealed comparable cell counts in both groups except day 15 after transplantation with significantly lower absolute counts in the ATG-G group ( (Fig. 1B) . On day 15 we observed high rates of CD8 T cell proliferation only in the ATG-G group, as shown by Ki67 staining ( Fig. 1C,D; 49.0% 76.8% in ATG-G group versus 11.0% 72.6% in noATG-G group on d þ15, p o0.01). We then compared proliferative activity of CD45RA þ and CD45RA À CD8 T cells within the ATG-G group. Proliferation rates of CD45RA À CD8 T cell subsets were higher at all time points after transplantation as compared to CD45RA þ CD8 T cell subsets with significant differences on days 60, 90 and 180 (Fig. 1E,F) . At day 15 CD45RA þ CD8 T cells also showed a strikingly high proportion of Ki67 þ cells (35.1%7 7.7%).
However, at day 30 this share dropped (3.2% 70.9%) and remained low. Next, we used a gating strategy originally suggested by Sallusto et al. [4] Fig. 2A) . We observed significantly higher frequencies of EM CD8 T cells in the ATG-G group at all time points except d þ180 (Fig. 2B) . In contrast, frequencies of naive CD8 T cells were significantly lower in ATG-G treated patients compared to patients without ATG-G treatment at all time points post transplantation (Fig. 2C) . The frequencies of CM and effector CD8 T cells were comparable in both groups (Fig. 2D, E ).
Discussion
Investigating the impact of ATG-G as a T cell depleting strategy [2] , as expected we observed lower CD3 T cell counts in the ATG-G group. Considering the half-life of ATG-G (clearance to subtherapeutic levels by a median of 177 9 days [5] ), unsurprisingly there was only a significant difference of CD3 T cell counts early after alloHSCT. The observed persistent increase of CD8 T cell frequencies is likely to be mainly due to decreased CD4 T cell counts as previously described [1] . Analysis of the CD8 T cell compartment in detail revealed a shift towards high EM and low naive CD8 T cell frequencies in the ATG-G group. This shift was observed up to d þ180 after alloHSCT, suggesting indirect long-term effects resulting from ATG-G treatment. Low shares of naive CD8 T cells could be the consequence of a rapid transition into the memory pool or thymic impairment due to ATG-G as previously suggested for CD4 T cell regeneration [1] . The rapid increase of EM CD8 T cells appears to be driven mainly by homeostatic mechanisms in the ATG-G depleted host, since concomitant high rates of CD8 T cell proliferation were found around day 15 in the ATG-G group only. This hypothesis is supported by consistently higher proliferation rates of CD45RA À CD8 T cells as compared to CD45RA þ CD8 T cells within the ATG-G group. However, it has previously been shown that changes towards an EM phenotype from other subsets such as naive CD8 T cells are also induced by T cell receptor stimulation and that CM CD8 T cells undergo various phenotypic changes upon cytokine stimulation, amongst others towards an EM phenotype [6] . It cannot be excluded that both these mechanisms contribute to the expansion of the EM CD8 T cell subset. Yet, the same reports also support the notion that EM CD8 T cells are especially receptive to cytokine stimulation [6] thus favoring the hypothesis of homeostatic proliferation. In line with larger clinical studies demonstrating ATG-G efficacy especially for prevention of severe acute GvHD (reviewed in [7] ), acute GvHD-rates in both patient groups in our study were similar even though ATG-G treated patients were transplanted with MUD grafts as opposed to MRD grafts in the noATG-G group and thus were at higher risk of GvHD (acute GvHD ATG-G group versus noATG-G group: Grade I and II 58% versus 63%, Grade III and IV 17% versus 13%). Consequently, the initial T cell depletion by ATG-G limited GvHD in MUD transplantations as intended. Yet, this also suggests that the significant expansion of EM CD8 T cells in the ATG-G group is not driving GvHD. Results from mouse studies equally suggest that memory CD8 T cells are less potent in mediating acute GvHD than naive CD8 T cells [8] . EM CD8 T cells appear to be favorable over CM CD8 T cells in this respect in mice [9, 10] . Likewise, in vitro studies with human material from healthy donors indicate an increased alloreactivity of naive CD8 T cells as compared to memory CD8 T cells under certain conditions [11] . In summary, our data suggest that rapid recovery of CD8 T cells after ATG-G induced T cell depletion in alloHSCT patients is due to peripheral homeostatic proliferation of EM CD8 T cells and not due to accelerated regeneration of naive CD8 T cells. This leads to a characteristic shift to EM CD8 T cells that is not associated with higher rates of GvHD.
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